CN102166190A - Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes - Google Patents
Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes Download PDFInfo
- Publication number
- CN102166190A CN102166190A CN2011100935301A CN201110093530A CN102166190A CN 102166190 A CN102166190 A CN 102166190A CN 2011100935301 A CN2011100935301 A CN 2011100935301A CN 201110093530 A CN201110093530 A CN 201110093530A CN 102166190 A CN102166190 A CN 102166190A
- Authority
- CN
- China
- Prior art keywords
- paclitaxel
- tumor
- liposome
- dual
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention belongs to the field of biomedicine. In particular, the invention discloses paclitaxel nano liposomes of dual targeting tumor. The dual targeting paclitaxel nano liposomes consist of three parts: polypeptides of dual targeting tumor, lipid attachments and paclitaxel liposomes. The invention also discloses a method for preparing the paclitaxel nano liposomes of dual targeting tumor and application of paclitaxel nano liposomes to preparation of a tumor-inhibiting medicament.
Description
Technical field
The invention belongs to field of medicaments, more specifically, the invention discloses nanometer liposome of a kind of dual-target tumor and preparation method thereof.
Background technology
The M ﹠ M of malignant tumor is obvious ascendant trend in recent years, has become the principal disease that threatens human health and life.The report of international cancer research institution shows, in the period of 1975 to 2000, global cases of cancer number has increased by one times, and annual new cases are about 1,200 ten thousand, and dead patient surpasses 7,000,000.Cancer will leap to the primary cause of the death into the whole world in 2010, the year two thousand thirty the tumor patient number will be present three times, the new cases number will increase to 2000-2600 ten thousand.
Chemotherapy is one of main means in the malignant tumor Comprehensive Treatment, but the life span of rational chemotherapy strategy significant prolongation tumor patient is greatly improved patient's life quality.Paclitaxel is a kind of diterpene-kind compound, be the natural product that from the Pacific yew bark, obtains the earliest, because of it can stablize the microtubule of tumor cell, suppress mitosis and have unique active anticancer (Wani, M.C., et al., Plant antitumoragents.VI.The isolation and structure of taxol, a novel antileukemicand antitumor agent from Taxus brevifol ia.J Am Chem Soc, 1971.93 (9): p.2325-7.), be widely used in ovarian cancer (Thomas at present, H.and P.Rosenberg, Roleof weekly paclitaxel in the treatment of advanced ovarian cancer.CritRev Oncol Hematol, 2002.44Suppl:p.S43-51.), breast carcinoma (Saloustros, E., D.Mavroudis, and V.Georgoulias, Paclitaxel and docetaxel in thetreatment of breast cancer.Expert Opin Pharmacother, 2008.9 (15): p.2603-16.), incidence cancer (Aisner, J.and H.Cortes-Funes, Paclitaxel in headand neck and other cancers:future prospects.Semin Oncol, (1997.24 1Suppl 2): p.S2-113-S2-115.) and the treatment (Greco of nonsmall-cell lung cancer, F.A., Paclitaxel-based combination chemotherapy in advanced non-small celllung cancer.Lung Cancer, 2001.34Suppl 4:p.S53-6.).But paclitaxel is a kind of liposoluble substance, in aqueous solution and other many solvents, all be difficult to dissolving (Ceruti, M., et al., Preparation, characterization, cytotoxicity and pharmacokinetics ofliposomes containing water-soluble prodrugs of paclitaxel.J ControlRelease, 2000.63 (1-2): p.141-53.).Formulation for paclitaxel (the Taxol of Shi Yonging clinically, commodity are called taxol) solvent that adopts is non-ionic surfactant polyoxyethylene Oleum Ricini (Cremophor EL, CrEL) and dehydrated alcohol (1: 1, V/V) mixture, but this dosage form is followed a lot of insoluble clinical problem (Hennenfent, K.L.and R.Govindan, Novel formulations of taxanes:areview.Old wine in a new bottle? Ann Oncol, 2006.17 (5): p.735-49.).The clinical practice of tradition formulation for paclitaxel can cause a series of anaphylaxis (Hennenfent, K.L.and R.Govindan, Novel formulations of taxanes:a review.Old wine in a new bottle? AnnOncol, 2006.17 (5): p.735-49.), the lighter shows pruritus, erythra, weight person shows as angioedema, hypotension, (Weiss such as respiratory failure, R.B., et al., Hypersensitivity reactions from taxol.J ClinOncol, 1990.8 (7): p.1263-8.Wiemik, P.H., et al., Phase I clinical andpharmacokinetic study of taxol.Cancer Res, 1987.47 (9): p.2486-93.).Patient's anaphylaxis more than 95% betide for the first time or formulation for paclitaxel administration for the second time during, 80% symptom betides preceding 10 minutes of infusion of drug, and often paclitaxel only infusion 1mg.Because but the CrEL induced animal produces similarly reaction (Wiernik, P.H., et al., Phase I clinical and pharmacokinetic study oftaxol.Cancer Res, 1987.47 (9): p.2486-93.), the existence of therefore thinking CrEL has caused the generation of above-mentioned untoward reaction.And the relevant (Lorenz of the generation of untoward reaction with infusion velocity, W., et al., Histamine release and hypotensive reactions in dogs by solubilizing agents and fattyacids:analysis of various components in cremophor El and development of acompound with reduced toxicity.Agents Actions, 1982.12 (1-2): p.64-80.), can not eliminate anaphylactoid appearance but prolong the infusion time.Researcher is attempted substituting CrEL with other solvents, and as Polyethylene Glycol, but the existence of zoopery discovery Polyethylene Glycol can reduce the anti-tumor activity of paclitaxel.Therefore CrEL is still standard solvent (Wiernik, P.H., et al., Phase I clinical andpharmacokinetic study of taxol.Cancer Res, 1987.47 (9): p.2486-93.) of present paclitaxel.
Generally adopt the conventional pretreatment before heavy dose of glucocorticoid and histamine receptor antagonists use as it clinically, but its curative effect is still imprecise.The pharmacovigilance project Chinese medicine untoward reaction incident of Northwestern Univ USA's Feenberg medical college and report research (Research on Adverse Drug Events and Reports, RADAR) find, the U.S., Europe and Japan have reported after 171 examples are used the polyoxyethylene castor oil paclitaxel anaphylactoid case have taken place in the period of 1997 to 2007, wherein death (34%) takes place in 58 routine patients, 21 examples that adopted 96 example reports among the patient of pretreating scheme take place dead, and mortality rate reaches 22%.Research (the Michaud of BoehnkeMichaud etc., L.B., V.Valero, and G.Hortobagyi, Risks and benefitsof taxanes in breast and ovarian cancer.Drug Saf, 2000.23 (5): show also that p.401-28.) allergy of light disease can take place 40% the patient of still having an appointment after pretreating scheme adopts, patient's anaphylaxis of 3% can be fatal.The execution of pretreating scheme has simultaneously limited tumor and has merged the use of the patient of ulcer, diabetes, hypertension etc. to this medicine, and the use of hormone also may increase the relevant mortality rate of treatment in the pretreating scheme.
Adopt CrEL also can cause peripheral nervous system toxicity (Onetto, N., et al., Overview of Taxol safety.J Natl Cancer Inst Monogr, 1993 (15): p.131-9.) as solvent.Electrophysiologic study finds that paclitaxel CrEL solution uses the patient that peripheral neuropathy takes place in the back to have aixs cylinder degraded and demyelination.Peripheral neuropathy can take place in 25% the patient of having an appointment behind the cyclosporine CrEL solution intravenously administrable, oral administration does not then have this untoward reaction and occurs, and CrEL and without gastrointestinal absorption (de Groen, P.C., et al., Central nervous system toxicity after liver transplantation.The role of cyclosporineand cholesterol.N Engl J Med, 1987.317 (14): p.861-6.).The CrEL plasma concentration that the paclitaxel of therapeutic dose or cyclosporine CrEL solution are produced can cause the swelling of mice dorsal root ganglion neurons aixs cylinder, vacuolar degeneration and degraded (Windebank, A.J., M.D.Blexrud, and P.C.de Groen, Potentialneurotoxicity of the solvent vehicle for cyclosporine.J Pharmacol Exp Ther, 1994.268 (2): p.1051-6.).Present studies show that, the epoxyethane derivative that CrEL produces is the topmost factor (Brat that causes nerve injury, D.J., A.J.Windebank, and S.Brimijoin, Emulsifier forintravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonaltransport and leads to structural abnormalities in differentiating N1E.115neuroblastoma.J Pharmacol Exp Ther, 1992.261 (2): p.803-10.).
Paclitaxel CrEL solution is inferior on every Wendesdays, each usage of 3 hours of infusion makes the plasma concentration of paclitaxel exceed body and removes metabolic ability, therefore the elimination in vivo of paclitaxel CrEL solution is nonlinear kinetics, also be called zero-order elimination kinetics (Sparreboom, A., et al., Cremophor EL-mediatedalteration of paclitaxel distribution in human blood:clinical pharmacokineticimplications.Cancer Res, 1999.59 (7): Tellingen p.1454-7.van, O., et al., CremophorEL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.Br JCancer, 1999.81 (2): p.330-5.).Zoopery confirms, relevant (the Sparreboom of paclitaxel nonlinear pharmacokinetics feature with CrEL, A., et al., Nonlinear pharmacokinetics of paclitaxel in miceresults from the pharmaceutical vehicle Cremophor
The resistance mechanism of paclitaxel is a lot, and it is one of important reasons that the expression of P-glycoprotein raises.The P-glycoprotein is by a kind of transmembrane transporter of multidrug resistance gene coding, has atpase activity, chemotherapeutics can be pumped in cell, reduces intracellular active drug concentration and causes drug resistance.There is research to think, CrEL can be by regulating the P-glycoprotein, suppress the expression of multidrug resistance gene and strengthen the antitumor action of paclitaxel, but (Woodcock does not in vivo succeed in the experiment, D.M., et al., Reversal of the multidrugresistance phenotype with cremophor EL, a common vehicle for water-insolublevitamins and drugs.Cancer Res, 1990.50 (14): p.4199-203.Schuurhuis, G.J., et al., The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.Br JCancer, 1990.62 (4): p.591-4.Friche, E., et al., The solvents cremophor EL andTween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascitestumor.Cancer Commun, 1990.2 (9): p.297-303.).Discover on the contrary, CrEL can be by the retardance cell cycle, reduce tumor cell to the picked-up of paclitaxel and the cytotoxicity (Liebmann of antagonism paclitaxel, J., et al., The influence of Cremophor EL on the cell cycle effects ofpaclitaxel (Taxol) in human tumor cell lines.Cancer Chemother Pharmacol, 1994.33 (4): p.331-9.).
Studies show that there is the problem of the stability and the compatibility in paclitaxel CrEL solution, just easily precipitate once the dilution paclitaxel as medicine; Can be from stripping plasticizer (divinyl hexyl phthalate) conventional PVC transfusion bag of using and the infusion pipeline clinically, therefore whole use must be adopted glass or non-PVC infusion device; With plastics or glass container non-specific adsorption or the like (Waugh is arranged, W.N., L.A.Trissel, andV.J.Stella, Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers.Am J HospPharm, 1991.48 (7): p.1520-4.Song, D., L.F.Hsu, and J.L.Au, Binding of taxol toplastic and glass containers and protein under in vitro conditions.J Pharm Sci, 1996.85 (1): p.29-31.).
In sum, the existence of CrEL has caused the appearance of a series of clinical toxicities in the existing dosage form of paclitaxel, CrEL also can produce complicated effect to the curative effect and the pharmacokinetics of paclitaxel, therefore press for clinically and develop the paclitaxel novel form that does not contain CrEL, to overcome the defective of surfactant.
Numerous scholars are devoted to the research and development of paclitaxel novel form, and the present novel form of having researched and developed success or having researched and developed comprises: albumin nano granular (Abraxame
TM) (Ibrahim, N.K., et al., Phase I andpharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.Clin Cancer Res, 2002.8 (5): p.1038-44.
Yamada, K., et al., Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3Weeks in Japanese Patients withSolid Tumors.Jpn J Clin Oncol, 2010.), prodrugs of paclitaxel docosahexenoic acid paclitaxel (Taxoprexin) (Wolff, A.C., et al., Phase I study of docosahexaenoic acid-paclitaxel:a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.ClinCancer Res, 2003.9 (10Pt 1): p.3589-97.); Polyglutamic acid paclitaxel (Xyotax
TM) (Sabbatini, P., et al., Phase II study of CT-2103 in patients with recurrent epithelialovarian, fallopian tube, or primary peritoneal carcinoma.J Clin Oncol, 2004.22 (22): p.4523-31.), paclitaxel analogs (BMS-184476 (Rose, W.C., C.Fairchild, and F.Y. Lee, Preclinical antitumor activity of two novel taxanes.Cancer Chemother Pharmacol, 2001.47 (2): p.97-105.), DJ-927Ono, C., A.Takao, and R.Atsumi, Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys.Biol Pharm Bull, 2004.27 (3): p.345-51.Baas, P., et al., Phase I/IIstudy of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advancednon-small cell lung cancer.J Thorac Oncol, 2008.3 (7): p.745-50.), BMS-275183 (Broker, L.E., et al., Effect of food on the pharmacokinetic behavior ofthe potent oral taxane BMS-275183.Clin Caneer Res, 2008.14 (13): p.4186-91.
Broker，L.E.，et?al.，Phase?I?trial?with?BMS-275183，a?novel?oral?taxane?withpromising?antitumor?activity.Clin?Caneer?Res，2006.12(6)：p.1760-7.)、OrtataxelCassinelli，G.，et?al.，Cellular?bases?of?the?antitumor?activity?of?the?novel?taxane?IDN5109(BAY59-8862)on?hormone-refractory?prostate?cancer.Clin?Caneer?Res，2002.8(8)：p.2647-54.Polizzi，D.，et?al.， A?novel?taxane?with?improved?tolerability?andtherapeutic?activity?in?a?panel?of?human?tumor?xenograf
Kurata, T., et al., Phase I and pharmacokinetic study of a new taxoid, RPR10988lA, given as a 1-hour intravenous infusion in patients with advanced solidtumors.J Clin Oncol, 2000.18 (17): p.3164-71.), paclitaxel micelle copolymer (Genexol-PM) (Kim, S.C., et al., In vivo evaluation of polymeric micellar paclitaxel formulation:toxicity and efficacy.J Control Release, 2001.72 (1-3): p.191-202.), paclitaxel vitamin E Emulsion (TOCOSOL), paclitaxel microsphere (Paclimer) (Lissianskaya, A., et al., Paclitaxelinjectable emulsion:Phase 2a study of weekly administration in patients withplatinum-resistant ovarian cancer.Journal of Clinical Oncology, 2004.22 (14): p.460s-460s.Bogdanova, N., et al., Paclitaxel injectable emulsion:Phase 2a study ofweekly administration in patients with non-small cell lung cancer (NSCLC) .Journalof Clinical Oncology, 2004.22 (14): p.649s-649s.), Paclitaxel liposome (power simplicity) etc.The part paclitaxel novel form (Abraxame that goes on the market wherein
TMGone on the market by FDA's approval in 2005; Taxusol-lipid muscle power is simple to be researched and developed successfully by Nanjing Cisco Pharmaceutical, in approval in 2003 listing at home), most of paclitaxel novel form still is in the preclinical study stage, or in the I-III clinical trial phase.
Therefore the common ground of above-mentioned paclitaxel novel form is to have avoided employing CrEL as solvent, has special advantages, as infusion time that can shorten medicine, reduce incidence rate of adverse reaction such as irritated, bone marrow depression and alopecia etc.The part dosage form be because therefore the change of structure and no longer be the effect substrate of P-glycoprotein can reduce the incidence rate of taxol resistance, part dosage form even can oral absorption.But it is on the knees of the gods that can paclitaxel novel form and paclitaxel conventional dosage forms compare the prognosis that improve tumor patient.
Summary of the invention
The present invention is intended to research and develop a kind of novel cancer target liposome drug-carrying nanometer particle, can improve the physicochemical character and the pharmacokinetics behavior of paclitaxel after the envelope paclitaxel, improve dissolubility, thereby avoid every toxicity that CrEL causes in the conventional formulation, pass through the tumor active targeting of this carrier simultaneously, increase the concentration of paclitaxel specifically, when strengthening antitumor action, reduce the toxicity of medicine normal histoorgan at tumor by local.
The present invention is encapsulated in paclitaxel in the nanometer liposome of dual-target tumor, and two target molecules can be kept original separately biologic activity, produce cooperative effect on function.
The paclitaxel nano lipid body of dual-target tumor provided by the invention mainly is made up of three parts, the polypeptide of dual-target tumor, lipid junctional complex and Paclitaxel liposome.
At first, the present invention adopts solid-phase synthesis to obtain the polypeptide of dual-target tumor, and described amino acid sequence of polypeptide is as follows: ARYC
RGDCFD
ATWLPPRARYC wherein
RGDCFDG: its core texture is the RGD tripeptides, and promptly arginine-glycine-aspartic acid (Arg-Gly-Asp) sequence is an integrin alpha V family at target spot.It is one of important member of cell adhesion molecule family that α V integrates element, activation and migration, the mediation endothelial cell proliferation by participating in endotheliocyte, suppresses endothelial cell apoptosis, participation basic fibroblast growth factor and the inductive angiogenesis of VEGF, induces number of ways such as the generation promotion neovascularization of cyclo-oxygenase 2 and developing of tumor.α V integrates and plainly to be low in immobilized vascular endothelial cell and the normal structure organ to express under physiological status, but high expressed is in activatory tumor vascular endothelial cell and tumor cell surface.Pharmaceutical carrier connects the ability that can significantly strengthen its target tumor new vessels behind the small peptide contain the RGD sequence.The ATWLPPR sequence be at target spot be VEGFR2 the neural endothelin-1 of co-receptor (Neuropilin-1, NRP-1).VEGFR-2 (Vascular Endothelial Growth Factor Receptor-2) is the VEGF/VEGFR family member, mainly discerns low-molecular-weight VEGF, plays an important role in migration of vascular endothelial cells, propagation, survival and vascular permeability are regulated.NRP-1 is-kind of non-tyrosine transmembrane glycoprotein, is that the coexpression of the accessory receptor of VEGFR-2 and VEGFR-2 can significantly promote combining of VEGF165 and VEGFR-2, strengthens the biological action of VEGF165 mediation, promotes the propagation of blood vessel endothelium.NRP-1 also high expressed is low and expresses in activatory tumor vascular endothelial cell and tumor cell surface in immobilized vascular endothelial cell and the normal structure organ under physiological status.
The present invention adopts the Fmoc solid-phase synthesis to synthesize polypeptide ligand-LYS-GLY-glycine-Palmic acid, and (lysine-glycine-glycine KGG-pal) connects thing, connects novel polypeptide and Paclitaxel liposome.
The present invention adopts the thin-film ultrasonic dispersion method to prepare Paclitaxel liposome, and press filtration method or high pressure homogenization method control liposome particle diameter are at 60-200nm.The nanoparticle of small particle diameter has its unique advantage as pharmaceutical carrier.The invasive growth of malignant tumor and shift the generation depend on blood vessel, though with respect to normal blood vessels, the tumor tissues medium vessels to the selectively penetrating power of medicine a little less than, maximum gauge still is no more than 400nm.The liposome of big particle diameter is more holding back of spleen, removes sooner from blood, and the liposome that arrives tumor tissues obviously reduces.Therefore the easier effect that sees through vascular space performance arrival tumor by local of granule path length circulation medicinal liposome.
Cytology research confirms, the dual-target tumor Paclitaxel liposome that contains RGD and ATWLPPR sequence of the present invention, and because of novel targeted polypeptide molecular weight is little, core medicine carrying grain diameter is controlled at 60-200nm, enters tumor tissues so easily penetrate endothelial cell barrier.Studies confirm that RGD and ATWLPPR sequence connect the rear space conformation and be independent of each other, and can keep the original separately biologic activity of sequence, thereby produce cooperative effect.Compared to the single targeting Paclitaxel liposome that only contains RGD or ATWLPPR sequence, the Paclitaxel liposome of the dual-target tumor of research and development has significantly and to be excellent and specificity adhesion new vessels endotheliocyte and tumor cell.Compare with the Paclitaxel liposome of no targeting and single target tumor, the Paclitaxel liposome of dual-target tumor has stronger and new vessels endotheliocyte and tumor cell specific binding ability, and suppress the tumor growth ability, so can further be applied to the targeted therapy field of malignant tumor.
Description of drawings
Fig. 1: the Paclitaxel liposome sem photograph of dual-target tumor
Fig. 2: the Paclitaxel liposome particle size distribution figure of dual-target tumor
Fig. 3: Taxol and each Paclitaxel liposome cellular uptake figure
Fig. 4: Taxol and each Paclitaxel liposome MTT detect figure
Fig. 5: Taxol and each Paclitaxel liposome press down tumor experiment D60 tumor multigraph
The specific embodiment
Experiment material
1, reagent, medicine and cell
(cholesterol is CHOL) available from German Dong Shang company for Ovum Gallus domesticus Flavus lecithin (egg phosphatide, egg PC), cholesterol; Mono methoxy polyethylene glycol 2000 DSPE mPEG2000-DSPE are available from U.S. Avanti Polar Lipids company; The lipid polypeptide is synthetic by the biochemical (Shanghai) Co., Ltd. of gill; Taxol is available from Shi Guibao company; Paclitaxel is available from last Hiroad standing grain medical sci-tech Development Co., Ltd; Sodium lauryl sulphate (Sodium dodecyl sulfonate, SDS), polyacrylamide, sucrose, glacial acetic acid, silver nitrate, glutaraldehyde, aprotinin etc. be all available from Shanghai branch company of traditional Chinese medicines group; HUVEC (Human umbilical vein endothelial cells), ATCC No.:CRL-2873; A549 cell (lung adenocarcinoma cell system), ATCC No.:CCL-185; DMEM (Dulbecco ' s Modified Eagle Media, high sugared cell culture medium), available from Invitrogen company; New-born calf serum is available from Austrian PAA company; Penicillin, streptomycin, trypsin etc. are available from magnificent company.
2, instrument and equipment and consumptive material
MillexTM FH pin type filter and Ultracel YM100 ultrafiltration pipe (U.S. Millipore company); SK5210HP water-bath Ultrasound Instrument (Shanghai High Kudos Science Instrument Co., Ltd.); R502B Rotary Evaporators (Taikan, Xi'an instrument and equipment company limited); JEM-1200EXII type transmission electron microscope (Japanese JEOL company); Quanta 200FEG field launch environment scanning electron microscope (FEI Co.); MASTERSIZER 2000 laser particle analyzers (Britain Malvern company); Freezer dryer 6L (U.S. Labconco company); Surplus the same.
3, solution preparation
PBS liquid (0.01M, pH7.4): NaCl 8.0g; KCl 0.2g; Na2HP0412H20 1.44g; KH2PO4 0.24g; Ultra-pure water 800ml; Regulate pH value to 7.4, be settled to autoclaving behind the 1L, 4 ℃ of preservations.
0.25% trypsinization liquid (1L): pancreatin 2.5g; NaCl 8g; KCl 0.4g; Na2HP0412H20 0.06g; KH2PO4 0.06g; NaHCO3 0.35g; Phenol red 0.02g; The pressure filtration degerming is preserved DMEM culture medium (1L) for-20 ℃ after the packing: 2 bags in DMEM powder; NaHCO37.4g; Penicillin 0.12g; Streptomycin 0.2g; HCl, NaOH regulate pH value to 7.2-7.4, pressure filtration degerming, 4 ℃ of preservations; Cells frozen storing liquid: DMEM culture medium 70%; Dimethyl sulfoxine (DMSO) 10%; New-born calf serum 20%;-20 ℃ of preservations after the packing; Cell pyrolysis liquid: Tris 10mmol/L; Nacl 100mmol/L; EDTA 1mmol/L; EGTA 1mmol/L; NaF 1mmol/L; Na4P2O710H2O 20mmol/L; Vanadic acid sodium 2mmol/L; Triton X-1001%; Glycerol 10%; Sodium lauryl sulphate 0.1%; Dexycholate 0.5%; PMSF 100 μ g/ μ L.
Further specify the present invention by following examples, but not as restriction of the present invention.
Embodiment 1: the synthesis step of dual-target oncopeptide
Adopt 9-fluorenylmethyloxycarbonyl (fluorenylmethyloxycarbonyl, FMOC) polypeptide of the synthetic dual-target tumor of solid-phase synthesis, (high performance liquidchromatography, HPLC) method purification adopt mass spectrum to identify to adopt high performance liquid chromatography.Concrete synthesis step is as follows:
1) resin swelling: the FMOC-AA-Wang-Resin resin is put into reaction tube, add dimethyl formamide (N, N-dimethylformamide, DMF) (15ml/g) 30min;
Deprotection: inhale and abandon DMF, add 20% piperidines DMF solution (15ml/g) 5min, add 20% piperidines DMF solution (15ml/g) 15min again after suction is abandoned;
2) detect: take out piperidine solution, get tens of resins, it is inferior to give a baby a bath on the third day after its birth with ethanol, adds 1,2,3-indantrione monohydrate, potassium cyanide, and each one of phenol solution, 105 ℃-110 ℃ heating 5min deepen blue positive reaction.
3) washing: DMF (10ml/g) twice, methanol (10ml/g) twice, twice of DMF (10ml/g);
4) condensation: protection aminoacid (FOMC-Asp-OH) three times is excessive, and two three times of the dimethylamine carboxyl benzotriazole tetrafluoride boron salt of 1-oxygen-3-are excessive, all with lack the DMF dissolving as far as possible, adds reaction tube, and it is excessive to add ten times of N-methylmorpholines at once, reacts 30min;
5) washing: DMF (10ml/g) once, methanol (10ml/g) twice, twice of DMF (10ml/g);
6) repetitive operation step 2)--6), connect FMOC-Tyr-OH, FMOC-Thr-OH, FMOC-Met-OH, FMOC-Asn-OH, FMOC-Pro-OH, FMOC-Arg-OH, FMOC-Lys-OH, FMOC-Leu-OH, FMOC-Phe-OH successively;
7) last washing: DMF (10ml/g) twice, methanol (10ml/g) twice, DMF (10ml/g) twice, twice of DCM (10ml/g);
8) cracking: lysate (10ml/g) (contains TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%) 120min;
9) dry up washing: nitrogen dries up lysate as far as possible, ether washing six times, and room temperature volatilizes;
10) sealing ,-20 degree are preserved.
Gained is the white powder material, HPLC purification, purity＞95%;
Embodiment 2: the preparation of the Paclitaxel liposome of non-targeting, single targeting and dual-target tumor
Adopt the thin-film ultrasonic dispersion method to prepare each Paclitaxel liposome
Non-active targeting Paclitaxel liposome prescription: PC: CHOL: mPEG-DSPE: PTX 9: 1: 0.5: 0.33, initiatively the targeting Paclitaxel liposome adds different lipid polypeptide (ARYC in above-mentioned prescription
RGDCFDG-KGG, ARYC
RGDCFD
ATWLPPR-KGG) (be 1: 542) with total fat mol ratio.Because in patent 1 embodiment, polypeptide A TWLPPR and ATWLPPR-fluorescent lipid body all do not demonstrate and are better than polypeptide A RYC
RGDCFDG, ARYC
RGDCFDG-fluorescent lipid body and polypeptide A RYC
RGDCFD
ATWLPPR, ARYC
RGDCFD
ATWLPPR-fluorescent lipid body with the cell-specific affinity, so synthetic, and in follow-on test, also do not give application.
Above-mentioned prescription is dissolved in chloroform, and the dull and stereotyped filter of 0.2 μ m filters, and puts the follow-up continuous vacuum draw of Rotary Evaporators 37 ℃ of rotations film forming and further removes chloroform in 1 hour; 9% sucrose solution that adds an amount of filtration sterilization, fully being swelling to thin film comes off, the gained suspension divides to be filled to cillin bottle after Mini-extruder extrudes (1 μ m, 0.4 μ m, 0.2 μ m, 0.1 μ m each 10 times), puts in the vacuum freeze drier,-38 ℃ * 2h,-35 ℃ * 18h ,-16 ℃ * 2h, 20 ℃ * 2h, the capping of jumping a queue after the drying ,-20 ℃ of refrigerators are preserved stand-by.Freeze-dried lipidosome PBS redissolution liquid is all adopted in every detection.
Scanning electron microscope is seen two rounded or similar rounds of targeting Paclitaxel liposome, and granular size is consistent, particle diameter＜100nm (see figure 1).
Embodiment 3: the Paclitaxel liposome extracorporeal releasing experiment
Paclitaxel liposome and each 3ml of taxol (Taxol) of non-active targeting Paclitaxel liposome, single targeting and the dual-target tumor of redissolving put in the molecular weight 14KD bag filter, bag adds the aquesterilisa simulated in vivo environment that 20ml contains the 45g/L bovine serum albumin, constant temperature blender with magnetic force stirs (300rpm), it is standby to take out dialysis solution 80 μ L respectively in 30min, 1h, 2h, 4h, 6h, 8h, 24h, and the outer add-back 80 μ L of bag filter contain the aquesterilisa of 45g/L bovine serum albumin simultaneously.The dialysis solution that takes out adds the chromatographic grade methanol solution protein precipitation of 320 μ L, and whirlpool mixes back high speed centrifugation 13000g * 10min, gets the capable HPLC of supernatant and detects content of taxol.Detect the concentration of paclitaxel in each Paclitaxel liposome that redissolves before the dialysis and the Taxol solution simultaneously, with (in the dialysis solution in paclitaxel concentration/stock solution paclitaxel concentration) * 100% index as the measurement slow-release capability.
Found that (see figure 2), paclitaxel discharges the fastest from the CrEL adjuvant, and the 24h cumulative release reaches 15.96%.After paclitaxel adopts liposome as pharmaceutical carrier, external rate of release obviously reduces, the Paclitaxel liposome 24h cumulative release of Paclitaxel liposome, single targeting Paclitaxel liposome, dual-target tumor is respectively 4.40%, 4.55%, 3.6%, and slow releasing function is remarkable.Also point out simultaneously the lipid polypeptide chain to be connected to the structural intergrity of not destroying liposome behind the surface of liposome, enhanced sustained release performance can further improve paclitaxel pharmacokinetics behavior in vivo.
Embodiment 4: the cell endocytic experiment
HUVEC, A549 cell inoculation are in 24 orifice plates, 1 * 10
6/ hole, put incubator 24h and make cell attachment, every hole adds Taxol, Paclitaxel liposome, single targeting Paclitaxel liposome, two targeting Paclitaxel liposome (in paclitaxel 5 μ g) respectively, 4 in multiple hole, hatch 4h for 37 ℃, ice PBS liquid washing 2 times adds lysis liquid 100 μ L/ holes, collects lysate, add 100 μ L methanol solution protein precipitations, whirlpool mixing 5min, the centrifugal 30min of 10000g gets the capable HPLC of supernatant and detects intracellular content of taxol.
After Taxol and each Paclitaxel liposome and cell were hatched, the cellular uptake situation was seen Fig. 3.As seen from the figure, A549 cell and HUVEC are extremely low to the intake of traditional paclitaxel solution (Taxol), and content of taxol reaches HPLC and detects minimum (being respectively 5ng/ hole and 25ng/ hole).After paclitaxel is encapsulated in liposome, because liposome can have an effect by number of ways such as contact release, absorption, endocytosis, fusion, lipid exchange and cell, so increased the picked-up ability of cell to paclitaxel.A549 cell and HUVEC reach 145ng/ hole, 157ng/ hole respectively to the intake of non-targeting Paclitaxel liposome.The Paclitaxel liposome that connects the tumour-specific target polypeptide has further strengthened the picked-up ability of cell to paclitaxel, wherein A549 cell and HUVEC are respectively 212ng/ hole and 232ng/ hole to the intake of single target spot Paclitaxel liposome, and the intake of the Paclitaxel liposome of dual-target tumor is respectively 346ng/ hole and 319ng/ hole.Above-mentioned data are also pointed out simultaneously, and the ability of the Paclitaxel liposome of cellular uptake dual-target tumor is stronger, and the novel polypeptide of confirmation dual-target tumor has the adhesion with tumor cell, vascular endothelial cell better specificity.
Embodiment 5: cell toxicity test
A549 and HUVEC cell dilution to 4 * 10
4/ mL adds 96 orifice plates, and every hole 100 μ L put incubator 24h and make cell attachment; The DMEM culture fluid of employing serum-free is the working solution of final concentration 0.9375mg/L, 1.875mg/L, 3.75mg/L, 7.5mg/L, 15mg/L with the Paclitaxel liposome doubling dilution of Taxol, Paclitaxel liposome, single targeting Paclitaxel liposome, dual-target tumor, every hole adds working solution 100 μ L, puts cell culture incubator again and hatches 72h; Add the MTT liquid 20 μ l/ holes of 5mg/mL, hatch 4h in the incubator, the centrifugal 10min of 1500rpm, discard culture fluid, each hole adds DMSO200 μ L respectively, goes up microplate reader behind the decolorization swinging table mixing 30min, select wavelength 530nm to detect light absorption value, calculate IC50, formula is as follows:
Fig. 4 as seen, Taxol is respectively 6.027mg/L, 6.56mg/L to the IC50 value among A549 cell, the HUVEC; Paclitaxel liposome is respectively 3.37mg/L, 4.56mg/L to the IC50 value of two kinds of cells; The Paclitaxel liposome of single targeting Paclitaxel liposome, dual-target tumor is respectively 1.46mg/L, 1.16mg/L and 3.40mg/L, 3.25mg/L to the IC50 value of two kinds of cells.Strengthened the toxicity to tumor cell and vascular endothelial cell behind the results suggest taxusol-lipid surface connection blood-vessels target polypeptide, wherein the Paclitaxel liposome of dual-target tumor has the strongest cytotoxicity.
Embodiment 6: tumor-inhibiting action assessment in the body
A549 lung adenocarcinoma cell routine is cultured to exponential phase, and 0.25% trypsinization gets 1 * 10 after becoming cell suspension
7It is subcutaneous that/0.1mL is inoculated in the right axil of female Balb/c nude mice in 4 ages in week (18-20g), and the tumor body grows to 50mm
3-80mm
3Play the beginning administration.Nude mice is divided into 5 groups by the administration difference, 5 every group, gives the Paclitaxel liposome of normal saline, Taxol, Paclitaxel liposome, single targeting Paclitaxel liposome and dual-target tumor respectively in d1, d4, d8 days.Wherein the normal saline group gives normal saline 0.5mL, and the surplus dosage of respectively organizing is counted 7.5mg/kg by paclitaxel.Monitoring nude mice body weight (2 times/week), tumor body size (2 times/week) after the administration put to death all nude mices to d60, peels off the tumor body and weighs, and calculates tumor control rate.
Tumor size computing formula: gross tumor volume V=ab
2/ 2, wherein a is that major diameter of tumor and b are the minor axis of tumor, tumor control rate computing formula: (1-experimental group tumor is heavy)/matched group tumor heavy * 100%.
The result shows (see figure 5), and the nude mice of control group growth of xenografted that gives normal saline is rapid, and d60 reaches 1925mm
3, average tumor heavily is (1.62 ± 0.09g).Give Taxol and each Paclitaxel liposome group nude mice tumor volume growth is slow relatively, Taxol group d60 transplanted tumor average external volume is 1104mm
3, tumour inhibiting rate is 46.9%; Paclitaxel liposome group d60 transplanted tumor average external volume is 912mm
3, average tumor heavily is that (0.61 ± 0.10g), tumour inhibiting rate is 62.3%; The Paclitaxel liposome group tumor average volume of single targeting Paclitaxel liposome group and dual-target tumor further dwindles, and is respectively 590mm
3And 455mm
3, average tumor heavily is respectively (0.44 ± 0.07g) and (0.30 ± 0.04g), tumour inhibiting rate is respectively 72.8% and 81.5%.The polypeptide that confirms the dual-target tumor indirectly effectively is connected in the taxusol-lipid surface, has promoted the picked-up of tumor tissues to pharmaceutical carrier, has improved medicine in partial valid density, has strengthened the anti-tumor capacity of medicine.
Claims (3)
1. the paclitaxel nano lipid body of a dual-target tumor is characterized in that it mainly by the polypeptide of dual-target tumor, and lipid junctional complex and Paclitaxel liposome three parts are formed.
2. the preparation method of the paclitaxel nano lipid body of the described dual-target tumor of claim 1, the ARYCRGDCFDATWLPPR polypeptide that it is characterized in that at first synthetic dual-target tumor, synthesize the polypeptide junctional complex then, prepare the paclitaxel nano lipid body of dual-target tumor at last.
3. the application of the paclitaxel nano lipid body of the described dual-target tumor of claim 1 in preparation inhibition tumour medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100935301A CN102166190B (en) | 2011-04-14 | 2011-04-14 | Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100935301A CN102166190B (en) | 2011-04-14 | 2011-04-14 | Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102166190A true CN102166190A (en) | 2011-08-31 |
| CN102166190B CN102166190B (en) | 2013-04-10 |
Family
ID=44487636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100935301A Expired - Fee Related CN102166190B (en) | 2011-04-14 | 2011-04-14 | Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102166190B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103613671A (en) * | 2013-12-04 | 2014-03-05 | 厦门大学附属第一医院 | Al-18F mark fusion peptide and application thereof |
| CN105641711A (en) * | 2016-01-25 | 2016-06-08 | 四川大学 | Dual brain-targeted prodrug with organic-amine-modified vitamin C being carrier |
| CN108084269A (en) * | 2017-12-28 | 2018-05-29 | 桂林医学院 | A kind of self-assembling polypeptide nano-carrier and preparation method thereof |
| US11141421B2 (en) | 2018-01-29 | 2021-10-12 | Fujifilm Corporation | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer |
| US11369625B2 (en) | 2016-08-31 | 2022-06-28 | Fujifilm Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327190A (en) * | 2008-07-29 | 2008-12-24 | 北京大学 | Anti-tumor long-circulating target liposomes for injections |
| CN101830984A (en) * | 2009-03-10 | 2010-09-15 | 上海市肺科医院 | Double-targeted hybrid polypeptide for tumor diagnosis and treatment |
-
2011
- 2011-04-14 CN CN2011100935301A patent/CN102166190B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327190A (en) * | 2008-07-29 | 2008-12-24 | 北京大学 | Anti-tumor long-circulating target liposomes for injections |
| CN101830984A (en) * | 2009-03-10 | 2010-09-15 | 上海市肺科医院 | Double-targeted hybrid polypeptide for tumor diagnosis and treatment |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103613671A (en) * | 2013-12-04 | 2014-03-05 | 厦门大学附属第一医院 | Al-18F mark fusion peptide and application thereof |
| CN103613671B (en) * | 2013-12-04 | 2017-01-18 | 厦门大学附属第一医院 | Al-18F mark fusion peptide and application thereof |
| CN105641711A (en) * | 2016-01-25 | 2016-06-08 | 四川大学 | Dual brain-targeted prodrug with organic-amine-modified vitamin C being carrier |
| US11369625B2 (en) | 2016-08-31 | 2022-06-28 | Fujifilm Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
| CN108084269A (en) * | 2017-12-28 | 2018-05-29 | 桂林医学院 | A kind of self-assembling polypeptide nano-carrier and preparation method thereof |
| US11141421B2 (en) | 2018-01-29 | 2021-10-12 | Fujifilm Corporation | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102166190B (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruan et al. | Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma | |
| Lin et al. | GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy | |
| Zhao et al. | Nanotechnology for cancer therapy based on chemotherapy | |
| Belhadj et al. | Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment | |
| Banerjee et al. | Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy | |
| Gu et al. | The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells | |
| Fang et al. | EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo | |
| Jiang et al. | Solid tumor penetration by integrin-mediated pegylated poly (trimethylene carbonate) nanoparticles loaded with paclitaxel | |
| Gao et al. | Menthol-modified casein nanoparticles loading 10-hydroxycamptothecin for glioma targeting therapy | |
| Zeng et al. | Treatment of malignant brain tumor by tumor‐triggered programmed wormlike micelles with precise targeting and deep penetration | |
| US9371364B2 (en) | Dual-targeted therapeutic peptide for nasopharyngeal carcinoma, nanoparticles carrying same and uses thereof | |
| CN102166190B (en) | Paclitaxel nano liposomes of dual targeting tumor and method for preparing paclitaxel nano liposomes | |
| Liu et al. | Dynamic disordering of liposomal cocktails and the spatio-temporal favorable release of cargoes to circumvent drug resistance | |
| CA3062624C (en) | Quinic acid-modified nanoparticles and uses thereof | |
| Wang et al. | Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force | |
| CN103804472A (en) | Taxane medicinal precursor | |
| KR20180120220A (en) | Biodegradable amphiphilic polymers specifically targeting ovarian cancer, polymeric vesicle made therefrom and uses thereof | |
| CN101601695B (en) | Self-microemulsion nanometer composition of ganodenic acid extract and preparation method thereof | |
| Xu et al. | Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer | |
| Xu et al. | Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy | |
| CN102379848A (en) | Paclitaxel immune nano liposome and preparation method and application thereof | |
| Song et al. | Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and in vivo via manipulation of αvβ3-ligand binding | |
| US11622990B2 (en) | VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor | |
| Yang et al. | Current update of a carboxymethylcellulose-PEG conjugate platform for delivery of insoluble cytotoxic agents to tumors | |
| CN103800915B (en) | Associating carrier micelle of a kind of targeted integration element receptor and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20160414 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |